trending Market Intelligence /marketintelligence/en/news-insights/trending/TNQ_g8YwU8--jISrvQllVQ2 content esgSubNav
In This List

Roche's lung cancer drug improves survival in follow-on study

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Roche's lung cancer drug improves survival in follow-on study

Roche Holding AG's Alecensa helped people with a certain type of lung cancer live longer by almost two years compared to Pfizer Inc.'s Xalkori, or crizotinib, according to follow-up data from a phase 3 study.

The company's unit Genentech Inc. said the two years of follow-up data was from the phase 3 study, named Alex, in patients with anaplastic lymphoma kinase-positive, or ALK-positive metastatic non-small cell lung cancer, that compared Alecensa to Xalkori.

Genentech said Alecensa significantly reduced the risk of the disease progressing or death by about 57% compared to Xalkori. Patients on Alecensa lived for almost 34.8 months without the disease worsening, compared to 10.9 months for those on Xalkori.

Alecensa has been approved by the U.S. Food and Drug Administration and the European Commission to treat ALK-positive metastatic non-small cell lung cancer.